Abstract:Purpose TNF-related apoptosis-inducing ligand (TRAIL) functions as a soluble cytokine and has been demonstrated significant antitumor activity against a variety of cancer cell lines without toxicity to most normal cells. Cisplatin is a potent anticancer agent and is widely used in the clinical for treatment of human cancers. Adeno-associated virus (AAV2) is a promising gene delivery vehicle for its advantage of low pathogenicity and long-term gene expression. However, lack of tissue specificity caused low efficiency of AAV transfer to target cells. The promoter of human telomerase reverse transcriptase (hTERT) is a good candidate to enhance targeting efficiency of AAV in cancer cells. Although AAV-mediated TRAIL controlled by hTERT promoter (AAV-hTERT-TRAIL) has obvious antitumor activity, the tumor cannot be completely eradicated. In this study, we first examined the effectiveness of combination therapy of cisplatin and AAV-hTERT-TRAIL on human hepatocellular carcinoma (HCC) in vitro and in vivo. Methods For in vitro experiments, tumor cell lines were treated with cisplatin, virus, or both. The transgene TRAIL expression controlled by hTERT promoter was evaluated in BEL7404 HCC cell line. Cytotoxicity was performed by MTT analysis. Cell apoptosis was detected by flow cytometry analysis. The in vivo antitumor efficacy of combination treatment with cisplatin and AAV-hTERT-TRAIL was assessed in human hepatocellular carcinoma xenografts mouse model. Results The enhanced TRAIL expression was observed in BEL7404 cells treated with AAV-hTERT-TRAIL plus cisplatin. Treatment with both AAV-hTERT-TRAIL and cisplatin exhibited stronger cytotoxicity and induced more significant apoptosis in cancer cells compared with AAV-hTERT-TRAIL or cisplatin alone, respectively. Moreover, in animal experiments, the combined treatment greatly suppressed tumor growth and resulted in tumor cell death. Conclusions AAV-mediated therapeutic gene expression in combination with chemotherapy provides a promising therapeutic strategy for human cancers. These data suggest that combined use of AAV-hTERT-TRAIL and cisplatin may have potential clinical application.

Application of cisplatin combined with hTERT-HRP/IAA in medicament for treating cervical cancer cell

Enhanced Suicide Gene Therapy Using A Tumor-Specific Promoter in Combination with Cisplatin

Uses of gamma-ray combined phTERT-HRP/IAA in medicament for treating cancer of larynx

The Antitumor Efficiency of Zinc Finger Nuclease Combined with Cisplatin and Trichostatin A in Cervical Cancer Cells

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer

In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.

Harnessing the synergy of nanosecond high-power microwave pulses and cisplatin to increase the induction of apoptosis in cancer cells through the activation of ATR/ATM and intrinsic pathways

Synergistic Effects of a Novel Lipid-Soluble Extract from Pinellia Pedatisecta Schott and Cisplatin on Human Cervical Carcinoma Cell Lines Through the Regulation of DNA Damage Response Signaling Pathway.

Trastuzumab-Cisplatin Conjugates for Targeted Delivery of Cisplatin to Her2-Overexpressing Cancer Cells

[Htert Promoter Enhances the Radiosensitivity to Gene-Radiation Therapy of Human Laryngeal Carcinoma Transplanted in Nude Mice].

Electron Transfer-Based Combination Therapy of Cisplatin with Tetramethyl- P -Phenylenediamine for Ovarian, Cervical, and Lung Cancers

Synergistic Cytotoxic Effect of Immunotoxin HEL PE38KDEL and Cis Platin Against Tumor Cells

Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro

The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo

The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression.

Inhibitory effect of hTERT promoter regulated tumor targeting TRALL combined with chemo-radiotherapy on cervical cancer in vivo

Mutual Effect of Cisplatin and Radiation Used in Combination in Hep-2 Cells

Intervention Effects of Nedaplatin and Cisplatin on Proliferation and Apoptosis of Human Tumour Cells in Vitro